Summary
Diltiazem (DTZ) 5 mg/kg was given to rabbits either orally (n = 5) or intravenously (n = 6). Plasma concentrations and urinary excretion of DTZ and its metabolites were determined by a high performance liquid chromatography assay (HPLC) for 12 and 48 h post dose, respectively. The results showed that the metabolism and disposition of DTZ in rabbits was similar to that of humans, mean absolute bioavailability (F) of DTZ was approximately 30% and the systemic clearance was 64.0 ml/min/kg. The metabolism of DTZ between the two routes of administration was quantitatively different in that higher plasma concentrations of the metabolites were observed after the intravenous dose. This could be a result of incomplete oral absorption, higher clearance of DTZ and the metabolites during the first pass through the liver (i.e. higher sequential first pass effect), and/or extrahepatic metabolism. On the basis of the plasma concentration-time profiles and urinary excretion of DTZ and its metabolites, it is concluded that the rabbit is a suitable animal model to investigate the kinetics and metabolism of DTZ.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schroeder J.S., Hung J., Lamb I.H., Connolly S.J., Jutzy K.R., Goris M.L. (1985): Diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: A double-blind randomized and placebo-controlled study. Acta Pharmacol. Toxicol., 57 (Suppl II), 55–60.
Schwartz J.B, Abemethy D.R. (1987): Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension, Am. J. Cardiol., 59, 1111–1117.
Shenasa M., Fromer M., Faugere G., et al. (1987): Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndrome. Am. J. Cardiol., 59, 301–306.
Roberts R., Gibson R.S., Boden W.E., et al. (1989): Prevention of reinfarction subsequent to non-Q-wave infraction. J. Cardiovasc. Pharmacol., 13 (Suppl I), S36-S46.
Meshi T., Sugihara J., Sato Y. (1971): Metabolic fate of d-cis-3-acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochloride (CRD-401). Chem. Pharmacol. Bull, 19, 1546–1556.
Sugihara J., Sugawara Y., Ando H., Harigaya S., Etoh A., Kohno K. (1984): Studies on the metabolism of diltiazem in man. J. Pharmacobio. Dyn., 7,24–32.
Yabana H., Nagao T., Sato M. (1985): Cardiovascular effects of the metabolites of diltiazem in dogs. J. Cardiovasc. Pharmacol., 7,152–157.
Schoemaker H., Hicks P.E., Langer S.Z. (1987): Calcium channel receptor binding studies for diltiazem and its major metabolites. Functional correlation to inhibition of portal vein myogenic activity. J. Cardiovasc. Pharmacol., 9, 173–180.
Sugawara Y., Ohashi M., Nakamura S., et al. (1988): Metabolism of diltiazem. I. Structures of new acidic and basic metabolites in rat, dog and man. J Pharmacobio. Dyn., 11, 211–223.
Kiyomoto Y., Sasaki Y., Odawara A., Morita T. (1983): Inhibition of platelet aggregation by diltiazem: Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites. Circ. Res., 52 (Suppl I), 115–119.
Hoglund P, Nilsson L.-G. (1989): Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. Ther. Drug Monit., 11, 543–550.
Yeung P.K.F., Prescott C., Haddad C., et al. (1990): Pharmacokinetics and metabolism of diltiazem in healthy volunteers following a single oral dose. Submitted.
Boyd R.A., Chin S.K., Don-Pedro O., et al. (1989): The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin. Pharmacol. Ther., 46, 408–419.
Yeung P.K.F., Mosher S.J., Quilliam M.A., Montague T.J. (1990): Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits and rats. Drug Metab. Dispos., 18, 1055–1059.
Yeung P.K.F., Montague T.J., Tsui B., McGregor C. (1989): High performance liquid chromatographic assay of diltiazem and six of its metabolites in plasma. Application to a pharmacokinetic study in healthy volunteers. J. Pharm. Sci., 78, 592–597.
Gibaldi M., Perrier D. (1982): Pharmacokinetics (2nd edn). New York, Marcel Dekker.
Fleishaker J.C., Phillips J.P., Smith T.C., Smith R.B. (1989): Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects. Pharm. Res., 6, 379–386.
Oiaffman M., Brogden R.N. (1985): Diltiazem: A review of its pharmacological properties and therapeutic efficacy. Drugs, 29, 387–454.
Hoglund P., Nilsson L.-G. (1988): Physiological disposition of intravenously administered14C-labeled diltiazem in healthy volunteers. Ther. Drug Monit., 10, 401–409.
St-Pierre M.V., Xu X., Pang K.S. (1988): Primary, secondary and tertiary metabolite kinetics. J. Pharmacokinet Biopharm, 16, 493–527.
Caille G., Dube L.M., Theoret Y., Varin F., Mousseau N., McGilveray I.J. (1989): Stability study of diltiazem and two of its metabolites using a high performance liquid chromatographic method. Biopharm. Drug Dispos., 10, 107–114.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yeung, P.K.F., Mosher, S.J. & Pollak, P.T. Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration. European Journal of Drug Metabolism and Pharmacokinetics 16, 69–74 (1991). https://doi.org/10.1007/BF03189877
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189877